Impel Pharmaceuticals Inc. (NASDAQ:IMPL – Get Free Report) was the recipient of a large decrease in short interest in the month of August. As of August 31st, there was short interest totalling 505,100 shares, a decrease of 12.7% from the August 15th total of 578,800 shares. Approximately 6.5% of the company’s stock are short sold. Based on an average daily trading volume, of 875,100 shares, the days-to-cover ratio is presently 0.6 days.
Impel Pharmaceuticals Price Performance
IMPL stock traded down $0.06 during trading on Tuesday, hitting $0.58. 236,584 shares of the stock traded hands, compared to its average volume of 570,139. Impel Pharmaceuticals has a 1 year low of $0.29 and a 1 year high of $7.39. The firm’s 50 day moving average is $0.97 and its two-hundred day moving average is $1.27. The stock has a market cap of $13.75 million, a price-to-earnings ratio of -0.17 and a beta of 0.06.
Impel Pharmaceuticals (NASDAQ:IMPL – Get Free Report) last posted its earnings results on Friday, August 18th. The company reported ($0.31) earnings per share (EPS) for the quarter. The business had revenue of $6.58 million for the quarter. As a group, analysts anticipate that Impel Pharmaceuticals will post -3.4 EPS for the current fiscal year.
Hedge Funds Weigh In On Impel Pharmaceuticals
About Impel Pharmaceuticals
Impel Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine.
- Five stocks we like better than Impel Pharmaceuticals
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Hold-It-Forever AutoZone Pulls into Buy Zone
- Best Restaurant Stocks to Invest in Now
- Virtual Riches: 3 Stocks Leading the VR Revolution
- Short Selling: How to Short a Stock
- 5 eCommerce Companies that need to be on Your Watch List
Receive News & Ratings for Impel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.